inclusion criteria * age ≥18 years * laboratory-confirmed sars-cov-2 infection within the past 7 days or the presence of symptoms or physical examination signs providing high probability of covid-19 disease * patients must have adequate organ and marrow function measured within the last 6 months * subjects must have at least one of the following high-risk features for clinical deterioration: * hypertension * diabetes mellitus * moderate to severe chronic obstructive pulmonary disease, emphysema, cystic fibrosis, or asthma * cancer patients who have received any immunosuppressive drugs within a year from enrollment * sickle cell disease or thalessemia * age \> or = 50 * bmi \> or = 30 * living in a nursing home or long-term facility * underlying serious heart condition as determined by the treating physician * immunocompromised subject as defined by the treating physician or covid-19 telehealth treatment team exclusion criteria * severe or life threating covid * weight less than 45 kg. * pregnant or breast-feeding females * subjects on dialysis or with creatinine clearance \< 45 ml/min * existing dmid toxicity scale for determining severity of adverse events grade 3 or greater hepatic failure * previously documented moderate or severe retinopathy or macular degeneration * uncontrolled seizure disorder * prolonged qt, defined as qtc ≥470 milliseconds for men and as qtc ≥480 for women using bazett's formula * known allergy to artesunate, artemisia annua, hydroxychloroquine, macrolides, 4-aminoquinolines, camostat mesilate, or other agents to be used in the trial. * currently receiving any study medications for other indications * concurrent use of medication that would cause drug-drug interactions * patients with psychiatric illness/social situations that would limit compliance

inclusion criteria * age ≥18 years * laboratory-confirmed sars-cov-2 infection within the past 7 days or the presence of symptoms or physical examination signs providing high probability of covid-19 disease * patients must have adequate organ and marrow function measured within the last 6 months * subjects must have at least one of the following high-risk features for clinical deterioration: * hypertension * diabetes mellitus * moderate to severe chronic obstructive pulmonary disease, emphysema, cystic fibrosis, or asthma * cancer patients who have received any immunosuppressive drugs within a year from enrollment * sickle cell disease or thalessemia * age \> or = 50 * bmi \> or = 30 * living in a nursing home or long-term facility * underlying serious heart condition as determined by the treating physician * immunocompromised subject as defined by the treating physician or covid-19 telehealth treatment team exclusion criteria * severe or life threating covid * weight less than 45 kg. * pregnant or breast-feeding females * subjects on dialysis or with creatinine clearance \< 45 ml/min * existing dmid toxicity scale for determining severity of adverse events grade 3 or greater hepatic failure * previously documented moderate or severe retinopathy or macular degeneration * uncontrolled seizure disorder * prolonged qt, defined as qtc ≥470 milliseconds for men and as qtc ≥480 for women using bazett's formula * known allergy to artesunate, artemisia annua, hydroxychloroquine, macrolides, 4-aminoquinolines, camostat mesilate, or other agents to be used in the trial. * currently receiving any study medications for other indications * concurrent use of medication that would cause drug-drug interactions * patients with psychiatric illness/social situations that would limit compliance

inclusion criteria - age ≥18 years - laboratory-confirmed sars-cov-2 infection within the past 7 days or the presence of symptoms or physical examination signs providing high probability of covid-19 disease - patients must have adequate organ and marrow function measured within the last 6 months - subjects must have at least one of the following high-risk features for clinical deterioration: - hypertension - diabetes mellitus - moderate to severe chronic obstructive pulmonary disease, emphysema, cystic fibrosis, or asthma - cancer patients who have received any immunosuppressive drugs within a year from enrollment - sickle cell disease or thalessemia - age > or = 50 - bmi > or = 30 - living in a nursing home or long-term facility - underlying serious heart condition as determined by the treating physician - immunocompromised subject as defined by the treating physician or covid-19 telehealth treatment team exclusion criteria - severe or life threating covid - weight less than 45 kg. - pregnant or breast-feeding females - subjects on dialysis or with creatinine clearance < 45 ml/min - existing dmid toxicity scale for determining severity of adverse events grade 3 or greater hepatic failure - previously documented moderate or severe retinopathy or macular degeneration - uncontrolled seizure disorder - prolonged qt, defined as qtc ≥470 milliseconds for men and as qtc ≥480 for women using bazett's formula - known allergy to artesunate, artemisia annua, hydroxychloroquine, macrolides, 4-aminoquinolines, camostat mesilate, or other agents to be used in the trial. - currently receiving any study medications for other indications - concurrent use of medication that would cause drug-drug interactions - patients with psychiatric illness/social situations that would limit compliance

inclusion criteria - age ≥18 years - laboratory-confirmed sars-cov-2 infection within the past 7 days or the presence of symptoms or physical examination signs providing high probability of covid-19 disease - patients must have adequate organ and marrow function measured within the last 6 months - subjects must have at least one of the following high-risk features for clinical deterioration: - hypertension - diabetes mellitus - moderate to severe chronic obstructive pulmonary disease, emphysema, cystic fibrosis, or asthma - cancer patients who have received any immunosuppressive drugs within a year from enrollment - sickle cell disease or thalessemia - age > or = 50 - bmi > or = 30 - living in a nursing home or long-term facility - underlying serious heart condition as determined by the treating physician - immunocompromised subject as defined by the treating physician or covid-19 telehealth treatment team exclusion criteria - severe or life threating covid - weight less than 45 kg. - pregnant or breast-feeding females - subjects on dialysis or with creatinine clearance < 45 ml/min - existing dmid toxicity scale for determining severity of adverse events grade 3 or greater hepatic failure - previously documented moderate or severe retinopathy or macular degeneration - uncontrolled seizure disorder - prolonged qt, defined as qtc ≥470 milliseconds for men and as qtc ≥480 for women using bazett's formula - known allergy to artesunate, artemisia annua, hydroxychloroquine, macrolides, 4-aminoquinolines, camostat mesilate, or other agents to be used in the trial. - currently receiving any study medications for other indications - concurrent use of medication that would cause drug-drug interactions - patients with psychiatric illness/social situations that would limit compliance